Prevalence of Candida species in onychomycosis at a Tertiary Care Hospital Karachi

  • Shahida Kashif
  • Muhammad Irfan Khan
  • Mukesh Kumar
  • Fakhur Uddin Department of Microbiology, BMSI, JPMC, Karachi
  • Farhina Nasir
  • Suresh Kumar
Keywords: Candida, C. tropicalis, Dermatophytes, Non-albicans, Onychomycosis, Potassium hydroxide.

Abstract

Objective: This study was designed to determine the frequency of Candida in clinically diagnosed cases of onychomycosis.
Study Design: It was a cross-sectional study.
Setting: It was conducted in the Department of Microbiology, BMSI, JPMC, Karachi, in a period of one year with the collaboration of the Department of Dermatology, JPMC, Karachi.
Materials and Methods: A total of 328 clinical samples have been collected. The fungal isolates were identified according to standard microbiological procedures. Samples were processed for primary screening microscopic test by KOH 20% (potassium hydroxide solution) wet mount. Processing for mycological culture was done by using Sabouraud's dextrose agar (cycloheximide and chloramphenicol), without antibiotics and Dermatophytes test medium. Candida species identification will be achieved through the commercial test of the API ID 32C system.
Results: Prevalence of fungal species that isolated from the 328 samples, 14.33% were dermatophytes, 6.40% were non-dermatophytes mould, 23.70% were Candida, 4.87% were mixed growth and 50.30% were negative for growth. Among the 16 mixed isolates, 15 were Candida species, accounting for a total of 28.4% Candida isolates. Out of 93, Candida albicans were 52.68%. Of the 47.32%, 26.88%, 11.82%, 4.30%, 2.15% and1.07%, Candida non albicans C. tropicalis C. parapsilosis, C. glabrata, C. krusei, C. guilliermondii, and Candida utilis respectively.
Conclusion: A significant number of onychomycosis cases result from the Candida spp. and Candida albicans were the main species. However, Candida non-albicans species are emerging in onychomycosis. In this manner, legitimate conclusion of the pathogens of onychomycosis is vital for focused treatment.

References

1. Aghamirian MR, Ghiasian SA. Onychomycosis in Iran: epidemiology, causative agents and clinical features. Nippon Ishinkin Gakkai Zasshi. 2010; 51(1):23-9.
2. Lone R, Bashir D, Ahmad S, Syed A, Khurshid S. A study on clinico-mycological profile, aetiological agents and diagnosis of onychomycosis at a government medical college hospital in kashmir. J Clin Diagnos Res. 2013; 7(9):1983. doi: 10.7860/JCDR/2013/5969.3378
3. Del Rosso JQ. The role of topical antifungal therapy for onychomycosis and the emergence of newer agents. J Clin Aesth Dermatol. 2014; 7(7):10.
4. Ahmed R, Kharal SA, Durrani MA, Sabir M, Chang AH. Frequency of Candida in onychomycosis. J Pak Med Assoc. 2013; 63(3):350-3.
5. Otašević S, Barac A, Pekmezovic M, Tasic S, Ignjatović A, Momčilović S, Stojanović P, Arsic Arsenijevic V, Hay R. The prevalence of Candida onychomycosis in Southeastern Serbia from 2011 to 2015. Mycoses. 2016; 59(3):167-72 doi: 10.1111/myc.12448.
6. Eisman S, Sinclair R. Fungal nail infection: diagnosis and management. Br Med J. 2014; 348(7953):27-32.
7. Marais A, Osuch E. Common cutaneous dermatophyte infections of the skin and nails. South African Family Practice. 2017; 59(3):33-40.
8. Cengiz FP, Cevirgen Cemil B, Emiroglu N, bahalı A, Biyik Ozkaya D, Su O, Onsun N. Etiology of onychomycosis in patients, Turkey. J Am Pediatr Med Assoc. 2017 Jun 8. doi: 10.7547/16-139. Epub 2017 Jun 8
9. Suryawanshi RS, Wanjare SW, Koticha AH, Mehta PR. Onychomycosis: dermatophytes to yeasts: an experience in and around Mumbai, Maharashtra, India. Intern J Res Med Sci. 2017; 5(5):1959-63.
10. Sav H, Baris A, Turan D, Altinbas R, Sen S. The frequency, antifungal susceptibility and enzymatic profiles of Candida species in cases of onychomycosis infection. Microbial Pathogenesis. 2018; 116:257-62. doi: 10.1016/j.micpath.2018.01.036. Epub 2018 Feb 20.
11. Fich F, Abarzúa-Araya A, Pérez M, Nauhm Y, León E. Candida parapsilosis and Candida guillermondii: emerging pathogens in nail candidiasis. Indian J Dermatol. 2014; 59(1):24. doi: 10.4103/0019-5154.123485.
12. Narain U, Bajaj AK. Candida onychomycosis: Indian scenario. Intern J Advances Med. 2016; 3(3):638-642.
13. Mohammadi R, Mirhendi H, Hedayati MT, Badali H. Caspofungin-Non-Susceptible Candida orthopsilosis Isolated from Onychomycosis in Iran. Iranian J Public Health. 2017; 46(2):235.
14. Medina IR, Fuentes LR, Arteaga MB, Valcárcel FR, Arbelo FA, del Castillo DP, Suárez SD, Quintana OF, Gutiérrez BV, Sergent FS, Acosta-Hernández B. Pigeons and their droppings as reservoirs of Candida and other zoonotic yeasts. Revista Iberoamericana de Micologia. 2017 Oct 1;34(4):211-4. doi: 10.1016/j.riam.2017.03.001.
15. Jayatilake JA, Tilakaratne WM, Panagoda GJ. Candidal onychomycosis: a mini-review. Mycopathologia. 2009; 168(4):165-73. doi: 10.1007/s11046-009-9212-x.
16. Bedaiwy MY, Metwally MA, El Zawawy NA, Saba HE. Epidemiology, Causative Agents and Clinical Features of Onychomycosis in El-Gharbia Governorate. Egyptian J Bot. 2017; 57:187-196.
17. Husain MA, Alam MN, Joarder Y, Ferdous M. Correlation between clinical and mycological diagnosis of onychomycosis. J Pak Assoc Dermatol. 2018; 27(3):220-5.
18. Roe JN, Grammer TC, O'Neil MP, inventors; DEVICEFARM Inc, assignee. Onychomycosis treatment apparatus and method. United States patent application US 10/039,782. 2018.
19. Afsarian SM, Badali H, Shokohi T, Najafipour S. Molecular diversity of Candida albicans isolated from immunocompromised patients, based on MLST Method. Iranian J Public Health. 2015; 44(9):1262.
20. Malik NA, Raza N. Non-dermatophyte moulds and yeasts as causative agents in onychomycosis. J Pak Assoc Dermatol. 2016; 19(2):74-8.
21. Soltani M, Khosravi AR, Shokri H, Sharifzadeh A, Balal A. A study of onychomycosis in patients attending a dermatology center in Tehran, Iran. J de Mycologie Medi. 2015; 25(2):e81-7. doi: 10.1016/j.mycmed.2015.03.007. Epub 2015 May 4.
22. Deorukhkar SC, Saini S, Mathew S. Non-albicans Candida infection: an emerging threat. Interdisciplinary Perspec Infect Dis. 2014; 2014. doi: 10.1155/2014/615958.
23. Dubljanin E, Džamić A, Vujčić I, Grujičić SŠ, Arsenijević VA, Mitrović S, Čalovski IČ. Epidemiology of onychomycosis in Serbia: a laboratory‐based survey and risk factor identification. Mycoses. 2017; 60(1):25-32. doi: 10.1111/myc.12537. Epub 2016 Jul 29.
24. Pakshir K, Zomorodian K, Zakaei A, Motamedi M, Ghiasi MR, Karamitalab M. Molecular identification and in-vitro antifungal susceptibility testing of Candida species isolated from patients with onychomycosis. Current Med Mycol. 2015; 1(4):26.
25. Ramudamu M, Lyngdoh WV, Prasad A, Rajbongshi J, Durairaj E. A Study On The Mycological Profile Of Onychomycosis In A Tertiary Care Hospital In Northeast India. Indian J App Res. 2018 Aug 6;8(1):306-309.
Published
2021-09-30
How to Cite
1.
Kashif S, Khan M, Kumar M, Uddin F, Nasir F, Kumar S. Prevalence of Candida species in onychomycosis at a Tertiary Care Hospital Karachi. JRMC [Internet]. 30Sep.2021 [cited 27Oct.2021];25(3):405-8. Available from: https://journalrmc.com/index.php/JRMC/article/view/1692

Most read articles by the same author(s)